{"entity":{"id":"multitude-therapeutics","kind":"company","name":"Multitude Therapeutics","aka":["Multitude Therapeutics Inc."],"tldr":"Multitude Therapeutics is a China-based biotechnology company running 4 late-stage cancer trials of AMT-116, AMT-676 and AMT-253 in colorectal cancer, melanoma and non-small-cell lung cancer.","summary":"Multitude Therapeutics, based in Shanghai, China, is a biotechnology company. Multitude Therapeutics is a clinical-stage biotechnology company in China developing antibody-drug conjugate therapies for cancer, using its PAD molecular design platform and MabArray target discovery platform. On ClinicalTrials.gov it is the lead sponsor of 4 recruiting or active phase 2 and phase 3 interventional cancer trials, testing AMT-116, AMT-676, AMT-253 and AK112 in colorectal cancer, melanoma and non-small-cell lung cancer. The largest, NCT07474727 (A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer), plans to enrol 180 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.multitudetherapeutics.com"},{"label":"ClinicalTrials.gov: trials led by Multitude Therapeutics","url":"https://clinicaltrials.gov/search?lead=Multitude%20Therapeutics%20Inc."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["colorectal","melanoma","nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07474727","nct06209580","nct06782334"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Shanghai","country":"CN","companyType":"biotech","website":"https://www.multitudetherapeutics.com","stage":"growth","investors":[],"funding":[]},"route":"/companies/multitude-therapeutics/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"trial":[{"id":"nct07474727","kind":"trial","name":"A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer","route":"/trials/nct07474727/"},{"id":"nct07590531","kind":"trial","name":"AMT-116 in Combination With AK112 in Patients With Lung Cancer","route":"/trials/nct07590531/"},{"id":"nct06782334","kind":"trial","name":"AMT-116 in Patients with Solid Tumors","route":"/trials/nct06782334/"},{"id":"nct06209580","kind":"trial","name":"AMT-253 in Patients With Advanced Solid Tumours","route":"/trials/nct06209580/"},{"id":"nct07718737","kind":"trial","name":"Global, Multicenter Study of AMT-116 Versus Investigator's Choice in Participants With Advanced or Metastatic Non-squamous EGFR-Wildtype Non-Small Cell Lung Can","route":"/trials/nct07718737/"}],"drug":[{"id":"amt-116","kind":"drug","name":"AMT-116","route":"/drugs/amt-116/"}]}}